Cornerstone Therapeutics Acquires Exclusive U.S. Marketing Rights to PERTZYE® (pancrelipase) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis

Read the Press Release

Digestive Care, Inc. Launches a Co-Pay Assistance Program in Cooperation with CF Services Pharmacy.

Read the Press Release

PERTZYE® is the same formulation previously marketed as PANCRECARB® MS-16.

Digestive Care, Inc. is a fully integrated pharmaceutical company that is dedicated to developing unique pharmaceutical products to alleviate complications and symptoms of gastrointestinal disorders. The company's platform technology specializes in drug therapies that utilize novel methods of drug delivery systems.

Read the Press Release on Pertzye®.